Merck (MRK) – Globe Newswire
-
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023
-
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board
-
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
-
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
-
Merck Recognized for Responsible Entrepreneurship in the Netherlands
-
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Inte
-
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
-
Organon acquires Karolinska Development’s portfolio company Forendo Pharma at a total purchase price of USD 945 million provided fulfilment of all milestones
-
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Home BancShares, Valley National, Kraton Corporation, and Acceleron Pharma on behalf of Stockholders and Encou
-
ACCELERON PHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of XLRN and Encourages Investors to Contact the Firm
-
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
-
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
-
PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the Firm
-
Biopharma Leaders Unite to Stand with Science
-
Biopharma Leaders Unite to Stand with Science
-
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020
-
Virbac completes divestment of U.S. Rights to SENTINEL® brands to MSD Animal Health
-
Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
-
Virbac to divest U.S. Rights to SENTINEL® brands to MSD Animal Health
-
BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston
-
BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine
-
BriaCell Provides Update on Remarkable Responder
-
BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
-
BriaCell Completes Share Consolidation
-
BriaCell Therapeutics Corp. Announces Share Consolidation
-
NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)
-
NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)
-
BriaCell to Present at Biotech Showcase™ 2020 in San Francisco
-
BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
-
NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)
-
NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)
-
BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th
-
NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
-
NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
-
BriaCell Announces Voting Results of the Special Meeting of Shareholders
-
NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)
-
NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)
-
BriaCell Announces Closing of Non-Brokered Private Placement of $568,444
-
NexTech Appoints New Chief Financial Officer
-
BriaCell Therapeutics Corp. to File Amendment to Management Information Circular
-
BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
-
Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month
-
BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals
-
BriaCell Announces Private Placement of up to $600,000
-
BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®
-
BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
-
BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49
-
BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019
Back to MRK Stock Lookup
